A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma.

Tamura, Ryota; Morimoto, Yukina; Sato, Mizuto; Hikichi, Tetsuro; Yoshida, Kazunari; Toda, Masahiro

Tamura, Ryota; Morimoto, Yukina; Sato, Mizuto; Hikichi, Tetsuro; Yoshida, Kazunari; Toda, Masahiro.

Afiliação

Tamura R; Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Morimoto Y; Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Sato M; Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Hikichi T; OncoTherapy Science, Inc., 3-2-1, Sakado, Takatsu-ku, Kawasaki City, Kanagawa 213-0012, Japan.
Yoshida K; Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Toda M; Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.

Vaccines (Basel) ; 8(3)2020 Sep 02.

Article em En | MEDLINE | ID: mdl-32887369